Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zynex, Inc. (ZYXI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Zynex is a medical technology company that develops, manufactures, markets, and sells non-invasive medical devices for pain management and rehabilitation, along with non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. Its filings offer detailed insight into this business focus, its financial condition, and its capital structure.
For ZYXI, annual reports on Form 10-K and quarterly reports on Form 10-Q describe revenue from devices and supplies, operating expenses, impairment charges, and risk factors. In 2025, the company also filed a Form 12b-25 explaining a delay in filing its third-quarter Form 10-Q and indicating that it expected to disclose substantial doubt about its ability to continue as a going concern, citing limited cash resources and the impact of payer-related issues.
Current reports on Form 8-K are especially important for understanding Zynex’s recent developments. These filings include disclosures about leadership changes, strategic initiatives, impairment charges at Zynex Monitoring Solutions, and, critically, the company’s voluntary Chapter 11 filings in the United States Bankruptcy Court for the Southern District of Texas. Related 8-Ks describe a restructuring support agreement with holders of its 5.00% Convertible Senior Notes due 2026, details of a debtor-in-possession financing facility, and Nasdaq’s determination to delist Zynex’s common stock as a result of the Chapter 11 cases.
Stock Titan’s platform surfaces these filings in real time as they are posted to EDGAR and pairs them with AI-powered summaries that explain key points in clear language. Users can quickly see what each 8-K addresses, how a 10-K or 10-Q discusses revenue trends, impairment charges, or going-concern language, and where documents reference restructuring milestones and listing status. The filings page also helps users locate information related to Zynex’s convertible notes, debtor-in-possession obligations, and other material agreements disclosed in its reports.
For those analyzing ZYXI, this page offers a structured way to review Zynex’s regulatory history, from its medical device business description to its Chapter 11 restructuring steps and Nasdaq delisting process, with AI-generated highlights to reduce the time needed to interpret complex filings.
John T. Bibb, listed as both a Director and the company's Chief Legal Officer, filed an Initial Statement of Beneficial Ownership (Form 3) for Zynex Inc (ZYXI) reporting the event date 08/18/2025. The filing explicitly states that no securities are beneficially owned by the reporting person. The form is signed and dated 08/28/2025.
Zynex, Inc. appointed Vikram Bajaj as Chief Financial Officer and Treasurer and John Bibb as Chief Legal Officer and Secretary, effective August 18, 2025. Former CFO Dan Moorhead resigned that day and will leave the company on August 29, 2025.
Bajaj and Bibb each receive a $450,000 annual base salary and are eligible for an annual discretionary bonus targeted at 70% of base pay. Each is granted inducement equity awards with a grant date fair value of $2.5 million in restricted stock vesting after three years and $2.5 million in stock options vesting quarterly over four years, subject to continued employment and certain accelerated vesting triggers. They also receive six months of salary and health benefits plus a pro‑rated bonus if terminated without cause or for good reason. The board expanded from four to five members and elected CEO Steven Dyson as a director without additional compensation.
Zynex Inc. (ZYXI) – Form 4 filing, 29 Jul 2025. Chief Operating Officer Anna Lucsok reported two equity-compensation transactions.
- Restricted Stock Award: On 27 Jul 2025 Lucsok received 7,500 common shares under the 2017 Stock Incentive Plan. The grant vests in equal annual tranches over four years and was issued at $0 cost.
- Tax-Withholding Share Surrender: On 28 Jul 2025 the issuer withheld 3,793 shares (Code F) at an implied value of $2.56 per share to cover payroll taxes related to previously vested RSAs. This is not an open-market sale.
After the transactions, Lucsok directly holds 64,412 shares, most of which remain unvested. No derivatives were involved and there were no cash sales or purchases. The filing modestly increases insider ownership alignment but has immaterial dilution given Zynex’s overall share count. Investor impact is therefore limited and chiefly informative for governance monitoring.